Related Experiment Video
Updated: May 12, 2026

Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction
Published on: June 7, 2011
Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling
William M Yarbrough1, Rupak Mukherjee, G Patricia Escobar
1Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, and Procter and Gamble Pharmaceuticals, Mason, Ohio, USA.
Background:
A cause-and-effect relationship exists between matrix metalloproteinase (MMP) induction and left ventricular (LV) remodeling after myocardial infarction (MI). Whether broad-spectrum MMP inhibition is necessary and the timing at which MMP inhibition should be instituted after MI remain unclear. This study examined the effects of MMP-1 and MMP-7-sparing inhibition (sMMPi) on regional and global LV remodeling when instituted before or after MI.
Methods And Results:
Pigs instrumented with coronary snares and radiopaque markers within the area at risk were randomized to MI only (n=11) or sMMPi (PGE-530742, 10 mg/kg PO TID) begun 3 days before MI (n=11) or 3 days after MI (n=10). Eleven weight-matched noninstrumented pigs served as reference controls. At 10 days after MI, infarct size was similar between groups (47+/-3% of the area at risk). Marker area increased from baseline in the MI-only group (10+/-3%, P<0.05) but was unchanged with sMMPi. LV end-diastolic volume increased in the MI-only group (82+/-3 mL) compared with controls (56+/-3 mL, P<0.05) but was attenuated with pre-MI and post-MI sMMPi (69+/-3 and 69+/-4 mL, respectively, P<0.05). Collagen content increased in the infarct zone of the MI-only group (34+/-5%) compared with control (2+/-1%, P<0.05) but was reduced with pre-MI and post-MI sMMPi (24+/-1% and 23+/-2%, P<0.05). Collagen content increased in the border zone (12+/-2%) and decreased in the remote zone (3+/-1%) of the pre-MI sMMPi group compared with post-MI sMMPi values (7+/-1% and 5+/-1%, P<0.05).
Conclusions:
Inhibition of MMP-1 and -7 is not required to favorably influence LV remodeling after MI. Moreover, a temporal difference exists with respect to the timing of sMMPi and regional and global myocardial remodeling patterns after MI.
Insights
Selective matrix metalloproteinase (MMP) inhibition, sparing MMP-1 and MMP-7, can favorably influence left ventricular (LV) remodeling after myocardial infarction (MI). The timing of this selective MMP inhibition (sMMPi) impacts remodeling patterns.
Area of Science:
- Cardiovascular Research
- Myocardial Infarction
- Cardiac Remodeling
Background:
- Matrix metalloproteinase (MMP) induction is linked to left ventricular (LV) remodeling post-myocardial infarction (MI).
- The necessity of broad-spectrum MMP inhibition and optimal timing remain undetermined.
- This study investigates MMP-1 and MMP-7-sparing inhibition (sMMPi) effects on LV remodeling.
Purpose of the Study:
- To evaluate the impact of sMMPi on regional and global LV remodeling.
- To determine if initiating sMMPi before or after MI alters remodeling outcomes.
- To assess the necessity of inhibiting MMP-1 and MMP-7 for favorable LV remodeling.
Main Methods:
- Pigs underwent myocardial infarction (MI) and were randomized to MI only, sMMPi initiated pre-MI, or sMMPi initiated post-MI.
- Radiopaque markers tracked changes in the area at risk.
- LV remodeling was assessed at 10 days post-MI via infarct size, LV end-diastolic volume, and collagen content.
Main Results:
- Infarct size was similar across all MI groups.
- sMMPi attenuated LV end-diastolic volume expansion compared to MI only.
- Collagen content changes differed between pre-MI and post-MI sMMPi groups in infarct and remote zones.
Conclusions:
- Inhibition of MMP-1 and MMP-7 is not essential for beneficial LV remodeling post-MI.
- The timing of sMMPi initiation significantly influences regional and global myocardial remodeling patterns after MI.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Myocarditis III: Medical Management
Acute Coronary Syndrome IV: Interprofessional Care

